Hansoh Pharmaceutical Group Company Limited
3692
Rangering i aksjer
#908
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Aksjekurs
$4.41
Markedsverdi
$26.76B
Endring (1 dag)
0.35%
Endring (1 år)
-4.45%
Land
CN
Handel Hansoh Pharmaceutical Group Company Limited (3692)
Kategori
Healthcare
P/S-forhold for Hansoh Pharmaceutical Group Company Limited (3692)
P/S-forhold per October 2026 TTM: 10.23
Ifølge Hansoh Pharmaceutical Group Company Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 10.23. Ved slutten av 2023 hadde selskapet et P/S-forhold på 8.86.
P/S-historikk for Hansoh Pharmaceutical Group Company Limited fra 2016 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 10.23 | 30.26% |
| 2024 | 7.85 | -11.45% |
| 2023 | 8.86 | 7.29% |
| 2022 | 8.26 | -10.41% |
| 2021 | 9.22 | -56.89% |
| 2020 | 21.39 | 46.55% |
| 2019 | 14.60 | 15.43% |
| 2018 | 12.64 | -15.54% |
| 2017 | 14.97 | -18.32% |
| 2016 | 18.33 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -30.98% |
IN
|
